ALNY - התחייבויות לטווח ארוך של החברה Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals (ALNY) management effectively monetizes scientific developments in the field of RNA interference. The company's long-term debt on the current GURU.Markets platform chart demonstrates stability dynamics, where this indicator equals 2.38. High margins on orphan drugs and a monopoly status in treating rare pathologies provide the business with colossal scale and a steady influx of patients.

The indicator is calculated by aggregating all credit obligations with maturities exceeding twelve months from the balance sheet liabilities. This metric determines long-term financial stability and the leverage level of the capital structure. For Alnylam Pharmaceuticals (ALNY), such borrowings often serve as fuel for the commercialization of breakthrough RNA therapies. Analyzing the organization's long-term financial debt allows for an assessment of the balance between investment risk and the business's growth potential.